WU
30
-2
TXN
35
2
C
60
-2
CCL
72
2
SO
48
-2
L
58
3
CHD
34
-5
LEN
46
-3
LH
36
-3
CAH
41
-6
SLG
53
-2
EFX
46
2
APA
37
2
NVDA
54
3
AVY
51
-2
MOS
50
4
NOV
43
4
EL
37
-3
A
41
-3
GPC
37
-3
WU
30
-2
TXN
35
2
C
60
-2
CCL
72
2
SO
48
-2
L
58
3
CHD
34
-5
LEN
46
-3
LH
36
-3
CAH
41
-6
SLG
53
-2
EFX
46
2
APA
37
2
NVDA
54
3
AVY
51
-2
MOS
50
4
NOV
43
4
EL
37
-3
A
41
-3
GPC
37
-3
Financhill
Back

Knight Therapeutics Quote, Financials, Valuation and Earnings

Better Than Oil Stocks

CLICK HERE TO FIND OUT MORE
Sell
16

GUD.TO
Knight Therapeutics

Last Price:
5.28
Seasonality Move:
0.47%

7 Day Trial

ALL ACCESS PASS

$ 7

Zero Day Options Trade LIVE Tuesday at 2 p.m. ET!

Discover The Zero Day Loophole (BEFORE Tues at 2 p.m. ET!)

Knight Therapeutics Price Quote

$5.28

Knight Therapeutics Key Stats

Sell
16
Knight Therapeutics (GUD.TO) is a Sell
Day range:
$5.25 - $5.32
52-week range:
$5.07 - $6.23
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
1.54
P/B ratio:
0.69%
Volume:
68.6K
Avg. volume:
173.3K
1-year change:
1.54%
Market cap:
$532.2M
Revenue:
$328.2M
EPS:
$-0.29

How Much Does Knight Therapeutics Make?

Is Knight Therapeutics Growing As A Company?

  • What Is Knight Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 0.13%
  • What Is Knight Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is -0.99%

Knight Therapeutics Stock Price Performance

What Is Knight Therapeutics 52-Week High & Low?

Knight Therapeutics Price To Free Cash Flow

Is It Risky To Buy Knight Therapeutics?

Is Knight Therapeutics Cash Flow Positive?

  • What Is GUD.TO Cash Flow From Operations?
    Cash flow from operations (TTM) is $52.8M
  • What Is Knight Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is -$53.9M
  • What Is Knight Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$3M

Knight Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    GUD.TO return on invested capital is -3.69%
  • What Is Knight Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -3.18%
  • What Is GUD.TO Return On Equity?
    ROE is a measure of profitability and is -3.98%

Knight Therapeutics Earnings Date & Stock Price

Knight Therapeutics Competitors

Knight Therapeutics Dividend Yield

Knight Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: -99.07% 0%
Revenue: 13.21% 3.17%

Analyst Recommendations

Buy Recommendations: 3
Hold Recommendations: 1
Sell Recommendations: 0
Price Target: 7.09
Upside from Last Price: 34.2%

Major Shareholders

  • How many GUD.TO shares are owned by institutional investors?
    10.4M GUD.TO shares are owned by institutional investors
  • How many GUD.TO shares are owned by insiders?
    0 GUD.TO shares are owned by insiders